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Abstract
Mammography is an important tool in the early detection of breast cancer. However, the perceptual task is difficult and a
significant proportion of cancers are missed. Visual search experiments show that miss (false negative) errors are elevated
when targets are rare (low prevalence) but it is unknown if low prevalence is a significant factor under real world, clinical
conditions. Here we show that expert mammographers in a real, low-prevalence, clinical setting, miss a much higher
percentage of cancers than are missed when the mammographers search for the same cancers under high prevalence
conditions. We inserted 50 positive and 50 negative cases into the normal workflow of the breast cancer screening service
of an urban hospital over the course of nine months. This rate was slow enough not to markedly raise disease prevalence in
the radiologists’ daily practice. Six radiologists subsequently reviewed all 100 cases in a session where the prevalence of
disease was 50%. In the clinical setting, participants missed 30% of the cancers. In the high prevalence setting, participants
missed just 12% of the same cancers. Under most circumstances, this low prevalence effect is probably adaptive. It is usually
wise to be conservative about reporting events with very low base rates (Was that a flying saucer? Probably not.). However,
while this response to low prevalence appears to be strongly engrained in human visual search mechanisms, it may not be
as adaptive in socially important, low prevalence tasks like medical screening. While the results of any one study must be
interpreted cautiously, these data are consistent with the conclusion that this behavioral response to low prevalence could
be a substantial contributor to miss errors in breast cancer screening.
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Introduction
Mammographic screening is an important tool in the early
detection of breast cancer [1] but it is a difficult perceptual task
and error-prone [2] with reported false negative rates of 20–30%
[3,4]. The signs of breast cancer are often ambiguous and/or hard
to see, with some proportion of errors attributable to the
perceptual difficulty of the task. However, a significant proportion
of miss errors cannot be attributed to a lack of a clear signal. In
many cases, if disease is detected in the current exam, it can also
be seen in retrospect on the previous exam. These ‘‘retrospectively
visible’’ or ‘‘actionable’’ cancers could have been found but were
missed on that previous exam [5–7]. They are either errors in
perception (failures of search) [8], or alternatively errors in
interpretation. Here we consider one contributor to those failures,
namely the low prevalence of disease in screening mammograms.
Breast cancer screening by mammography is a difficult visual
search task, characterized by a low prevalence of positive findings.
Experiments with non-experts in a laboratory setting show that
more targets are missed during vigilance tasks when observers
monitor displays for targets that appear infrequently [9,10].
Attention fluctuates and targets can come and go without being
noticed. More recently, it has been shown that these prevalence
effects occur in visual search tasks even though observers can view
displays for as long as they want. Even when observers must
actively reject a display before it will be removed, more targets are
missed at low prevalence than at higher prevalence [11].
The opposite type of error, false positives, tend to decline at low
prevalence [12] because the primary effect of prevalence is a
criterion shift, with observers in low prevalence situations less likely
to call an ambiguous stimulus a target and more likely to terminate
search [13]. In clinical settings, neither false positives nor false
negative errors are desirable but it seems reasonable to assert that
false negative errors are less desirable. Thus, if low prevalence
produces more false negative errors in a clinical setting, even if the
false positive errors decline, that would be important information.
It is important to note that prevalence effect could have two
different types of effect on performance in mammography [14–
16]. Gur and his colleagues have shown that, in a laboratory
setting, prevalence did not change the area under the receiver
operating characteristic curve (AUC) [14]. However, even if AUC
is unchanged, it would be of interest to find the change in the
pattern of errors that would follow a change in criterion, the bias
to call a case actionable or non-actionable. In reanalyzing the
2003 data, Gur et al. (2008) reported a change in confidence
ratings with prevalence that would be consistent with a criterion
shift and, as noted above, criterion shifts have been a hallmark of
prevalence effects outside radiology [15]. Our particular interest
was in looking for evidence for a prevalence effect in the clinic with
professionals carrying out a critical task in their area of expertise.
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There is evidence that prevalence is a factor for experts in
cervical cancer screening [17], a situation that, like mammogra-
phy, is characterized by a low prevalence of disease in the tested
population (estimated to be about 0.3%) [18–20]. The present
study was designed to compare error rates in mammography
under low prevalence, clinical conditions with rates under high
prevalence, laboratory conditions. Doing a study of this sort under
realistic clinical conditions is conceptually easy but difficult to
implement because of the need to minimize interference with the
normal clinical workload and the need to insert test cases
undetectably without violating patient rights. In order to measure
performance under true clinical conditions, 100 cases were
selected by study radiologist (RB): 50 with biopsy-confirmed
cancers and 50 determined to be negative based on two to three
years of stable negative findings. We introduced these cases into
the offline, regular screening workflow over a 9-month time period
(i.e. radiologists were reading these screening mammograms in a
batch a few hours or few days after their acquisition). We used this
very slow trickle of cases so as not to seriously alter the overall
prevalence of disease in this screening population. In the second
arm of the study, all of the same 100 cases were interpreted in a
single sitting by members of the same group of participating
radiologists.
Ideally, we would have tested high and low prevalence under
conditions that differed only in prevalence. Obviously, that is not
the case in this study where low prevalence cases were
unobtrusively slipped into the normal workflow while high
prevalence cases were read under laboratory conditions. Unfor-
tunately, the ideal version of this experiment is impossible. If the
high prevalence arm of the study was generated by adding cases
into clinical practice in order to boost prevalence to 50% or even
some much more modest level (e.g. 10%), clinicians would know
immediately that this was not normal clinical practice in a world
where cancer prevalence is normally about 0.3%. Nor can the low
prevalence arm be run under laboratory conditions. First, that
would lose the realism of testing in the clinic. Moreover, it would
be prohibitive in the lab to read the thousands of normal cases that
would be needed in order to have prevalence near 1%. The
present design is a compromise between the ideal and the possible.
It maintains the basic goal of reading the same 100 cases under
high and low prevalence conditions. We will return to these
concerns in discussing the results.
Within the constraints imposed by the real world, we show that
false negative errors are higher in the low prevalence clinical
setting than in the high prevalence, lab setting, suggesting that a
substantial portion of missed cancers may be missed because of the
properties of the human ‘search engine’.
Results
We measured false negative and false positive rates in both the
high and low prevalence settings. Because we could not control
which radiologist saw which case in the low prevalence arm, data
from the low prevalence arm was treated as if the entire 14-
radiologist practice constituted one experimental observer. No
radiologist in the low prevalence arm reported recognizing that an
inserted case was not a part of the normal workflow. Inclusion of
inserted cases in the low prevalence arm of the study raised disease
prevalence from ,0.3% to ,1% during the study period, a
change unlikely to influence prevalence effects5. These low
prevalence data were compared to the average performance of 6
observers that also participated in the high prevalence condition.
These 6 radiologists contributed 41% of the low prevalence
interpretations (see below).
We compared performance of the radiologists in the low and
high prevalence reading settings only after removing from high
prevalence analysis any case that a radiologist saw in both arms of
the study (though, in fact, this does not change the pattern of
results). As shown in Figure 1, the false negative rate was 12% at
high prevalence, rising significantly to 30% at low prevalence for
the same set of the 50 positive cases (x2(1) = 11.77, p,0.005). False
positives were lower at low prevalence, though the difference is not
significant (Low prevalence: 20%; High prevalence: 27%;
x2(1) = 3.04, p.0.05).
Of 15 cancers missed in low prevalence, seven (47%) were
found by all 6 observers that also participated in the high
prevalence arm of the study (Figure 2). Eight of the remaining
cancers missed at low prevalence were detected by at least one
radiologist at high prevalence. The pattern of significantly higher
false negatives and lower false positives during low target
prevalence compared to high target prevalence does not change
if analysis of low prevalence data is restricted to the 41% of cases
interpreted by the six radiologists who participated in both arms of
the study, though statistical power declines (shown as pale bars of
Figure 1).
Discussion
In mammography, cancers are missed for many reasons. Based
on the present results, we propose that the low prevalence of
disease is, itself, a source of misses. The same cancers that are
found when cancers are present on 50% of cases, are missed when
cancers are present on 1% of cases. Given the other differences
between the high and low prevalence arms of this study, it is
Figure 1. Error rates for rare targets (red bars, ,1% preva-
lence) and common targets (green bars, 50% prevalence) for
two types of errors, false negatives and false positives. The dark
colored bars represent data average over all 14 observers. The light red
bars represent low prevalence average errors (false negatives and false
positives) for the six observers who participated in both arms of the
study (low and high prevalence). The light green bars represent high
prevalence average errors (false negatives and false positives) restricted
to the cases that the six high prevalence observers did not also see
during the low prevalence arm of the study. Regardless of these
filtering of the data, low prevalence, false negative errors are markedly
higher than high prevalence false negative errors.
doi:10.1371/journal.pone.0064366.g001
Prevalence Effect in Mammography Screening
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Figure 2. One of the seven cases not seen at low prevalence but seen by all 6 readers at high prevalence. This is a case of a 56-year-old
woman whose test screening mammogram was presented with a prior mammogram taken two years earlier. The case was rated level 5 of difficulty,
the cancer was detected on the original screening and the lesion type is calcifications measuring 10 mm in size with the pathology of DCIS with
microinvasion. The parenchymal density is less dense. a) MLO (top 2 images) and CC (bottom two images). b) Lesion in right upper quadrant.
Magnification view shows pleomorphic calcifications in a segmental distribution.
doi:10.1371/journal.pone.0064366.g002
Prevalence Effect in Mammography Screening
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possible to argue that some factor, other than prevalence produced
the difference in the pattern of errors. That factor would need to
be a factor that provoked a higher miss rate when the clinician/
observers believed that they were doing their real job and a lower
miss rate when they were doing an experiment. It is unlikely that
motivation accounts for the difference between low and high
prevalence performance. If anything, we would expect motivation
to have been higher when apparently real patients were being
evaluated in the low prevalence arm of the study compared to the
obviously unreal, laboratory setting of high prevalence. Moreover,
the pattern of results closely mirrors other prevalence effects in
visual search. The miss (false negative) error rate goes up. The false
positive rate declines (albeit by a non-significant amount in this
study).
Under most natural circumstances, the effects of low prevalence
effect are probably adaptive. It is usually wise to be conservative
about reporting events with very low base rates. However, while
this response to low prevalence appears to be strongly engrained in
human visual search mechanisms, it may not be adaptive in
socially important, low prevalence tasks like medical screening.
Of course, prevalence is not the only source of false negative
errors. Other causes include failures of perception and/or the
analysis of perceived findings [21]. Clearly, technical problems
such as poor compression and positioning may lead to inability to
see and characterize lesions. Other errors can be attributed to
specific parenchymal patterns and lesion location: dense tissue
with lesion obscuration, location of lesion near edge of tissue or
edge of image, large breasts, and breasts with multiple findings; as
well as to challenges more specific to lesion type: subtle malignant
features, slow lesion growth, and small lesion size [4].
In this study, we add low prevalence to the list of causes. Most of
the cancers that were missed at low prevalence, were found at high
prevalence by all or at least one of the study radiologists. The
radiologists did not report remembering the cases and there are
data that suggest that it is unlikely that the cases would be
remembered when reread by the same radiologists [22–25].
Moreover, as noted above, the results are essentially the same if we
remove from analysis any data from a high prevalence case if the
observer had seen that case at low prevalence. This experiment
strongly suggests that a substantial prevalence effect can be found
outside the lab, when experts are performing important visual
search tasks under their normal working conditions. We included a
wide range of lesion types and sizes but did not find evidence that
the prevalence effect was limited to specific types of lesion or size.
Small numbers limit any significant analysis, however positive
cases missed at low prevalence but found by all (7 cancers) versus
cases missed by at least one reader (8 cases) at high prevalence
were rated more often at difficulty levels of 4 and 5 (86% vs. 38%)
and had less instances of dense breast parenchyma (43% vs. 63%)
(see Tables S1, S2 and S3 for more details).
As noted earlier, there are inevitable compromises in an
experiment that wants to examine the effects of low prevalence in
a clinical setting. Because, workflow demands meant that we could
not guarantee that a specific radiologist would see a specific
inserted case, we treated the entire practice as a single observer in
the low prevalence arm of the study. Ideally, the same observers
would have seen the same number of cases in both arms of the
study. This could not be done without disrupting ongoing clinical
work. Nevertheless, to the best of our knowledge, this is the only
study of prevalence where cases with ground truth were evaluated
under normal working conditions at low prevalence. Another
limitation of the design is that the comparison is done between a
clinical setting and a laboratory setting in which finding a cancer
would not alter management. However, as mentioned earlier, it is
impossible to test at high prevalence in a clinical screening setting.
In a future study, it might be valuable to compare performance on
cases inserted into screening to performance on cases inserted at
secondary evaluation stage where the real and perceived
prevalence of disease would be much higher, though that would
pose issues of its own.
Our method for inserting known cases into the regular workflow
has potential to be a part of a quality assessment audit system. For
the present study, this was a challenging ad hoc process with
fictitious names and numbers generated, linked to images, with
appropriate history and records and then blocked from any official
interpretation. However, if made into a routine practice, this
method could provide a relatively unobtrusive mode for individual
and/or group assessment. Such a method, using cases where ‘gold
standard’ truth is known, could address some of the variability in
estimates of rates of missed cancers. For example, in the
retrospective analysis, there are differences among cancers that
are deemed ‘‘missed’’ that depend on whether or not the reviewer
is blinded to the later positive case at the time they assess the
earlier ‘‘negative’’ case with miss rates ranging from 10 to as high
as 35% [6,7].
In summary the results illustrate how unanticipated conse-
quences can arise when civilization designs an artificial but
important visual search task like breast cancer screening or, for
that matter, airport baggage screening, bridge fatigue examina-
tions, etc. The present results indicate that the normal response of
the human mind to low probability events could be a substantial
contributor to false negative errors in breast cancer screening.
What can be done? General methods suggested to improve
performance include training, experience, continuing education,
prospective double reading, retrospective evaluation of missed
cases, or computer-aided detection, and at least in some
populations, the use of digital rather than film-screen imaging
[19,26]. In the specific case of prevalence effects, in the laboratory,
it is possible to manipulate these effects, for example, by presenting
an observer with a burst of high prevalence images prior to low
prevalence search [12]. Given the present results, we should now
determine if there are practical changes in clinical settings that can
reduce errors due to target prevalence.
Materials and Methods
Study Participants
Fourteen board certified radiologists with expertise in breast
imaging (5 to 30 years of experience) in a large academic hospital,
actively engaged in the daily practice of breast-image screening
agreed to participate in the study. This prospective study was
reviewed and approved by Brigham and Women’s Hospital
Institutional Review Board and was HIPPA compliant. All
participants gave written informed consent to participate in a
prospective study and a subgroup of participants agreed to
participate in a later retrospective laboratory study. We have
complied according to the principles expressed in the Declaration
of Helsinki in the treatment of our participants.
Study Material
The 100 mammograms (50 positive, 50 negative) used in both
phases of the study were acquired with GE digital mammography
equipment and presented on the GE Seno Advantage 2.1
workstation in DICOM format. All the cases included at least 4
images (left and right breast mediolateral oblique (MLO) views
and craniocaudal (CC) views) and 46% of them included historical
prior mammograms for comparison. When selecting cases the
study radiologist made an effort to include different tumors types
Prevalence Effect in Mammography Screening
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(e.g. masses, calcifications, etc.) and different levels of subjectively
assessed difficulty. CAD overlays were used. Header files of the
images were populated with fictitious names, dates of birth,
requisition number and any other information that might point to
the real identity of the patient. True year of birth was preserved.
Fictitious unique identifier numbers were created for all cases.
Only if participating radiologists attempted to enter a final
abnormal report, were they informed that this was an inserted
case.
The 50 positive mammograms were either screen-detected
cancers, confirmed with later biopsy, or mammograms done 1 to 2
years prior to a screen-detected cancer that had been interpreted
as negative. In these latter cases, the lesion was determined to be
retrospectively visible by the study radiologist (see Tables S1, S2
and S3 for details about these cases). The other fifty cases of the
100 study cases used had no evidence of cancer for at least 2 years
beyond the mammograms that were chosen for the study and were
thus characterized as normal. For present purposes, the most
important point is that the same 100 cases were seen in low and
high prevalence arms of the study.
Procedure
During both the low and high prevalence study phases,
radiologists evaluated one case at a time. They decided whether
to recommend further evaluation or not using the standard
methods of reporting, and indicated the location of lesions, if
present, on the image. In the low prevalence setting (,1%), each
of the 100 study cases was added surreptitiously to the normal off-
line screening workflow. Each case was added only once to the
normal flow and, therefore, interpreted by only one of the 14
participants. Each of the 14 radiologists saw on average eight of
the test cases. In the high prevalence arm of the study that took
place nine months after the end of the low prevalence arm, six of
the fourteen radiologists each interpreted all 100 test cases in a
laboratory setting over approximately three hours. In this arm,
prevalence was 50% and observers necessarily knew that they were
in a study and were not carrying out their clinical duties. The
selection of six radiologists for this arm of the study was random
and based on their availability without prior knowledge of their
performance in the low prevalence arm of the study.
Data Analysis
The main outcome measures were false negative and false
positive rates as a function of target prevalence. False negative
cases were considered those with visible cancers, reported as
negative. The false positives were those known-negative mammo-
grams reported as abnormal. The data were analyzed for statistical
significance using the chi-squared test.
Supporting Information
Table S1 Characteristics of all 50 positive cases used in
both arms of the study.
(DOCX)
Table S2 Characteristics of the 7 positive cases that
were missed in low prevalence arm of the study and fond
by all observers in the high prevalence arm of the study.
(DOCX)
Table S3 Characteristics of 8 positive cases that were
missed in the low prevalence arm of the study and found
by at least one observer in the high prevalence arm of
the study.
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